Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010));CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]

European Urology

Volumn 72, Issue 6, 2017, Pages 962-971

  Escudier, Bernard ^a   Sharma, Padmanee ^b   McDermott, David F ^c   George, Saby ^d   Hammers, Hans J ^e,t   Srinivas, Sandhya ^f   Tykodi, Scott S ^g   Sosman, Jeffrey A ^h,u   Procopio, Giuseppe ⁱ   Plimack, Elizabeth R ^j   Castellano, Daniel ^k   Gurney, Howard ^l   Donskov, Frede ^m   Peltola, Katriina ⁿ   Wagstaff, John ^o   Gauler, Thomas C ^p   Ueda, Takeshi ^q   Zhao, Huanyu ^r   Waxman, Ian M ^r   Motzer, Robert J ^s  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DANA FARBER HARVARD CANCER CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f STANFORD CANCER INSTITUTE   (United States)

^g USA   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j FOX CHASE CANCER CENTER   (United States)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l WESTMEAD HOSPITAL   (Australia)

^m AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁿ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^o SWANSEA UNIVERSITY   (United Kingdom)

^p UNIVERSITY HOSPITAL ESSEN   (Germany)

^q CHIBA CANCER CENTER   (Japan)

^r BRISTOL MYERS SQUIBB   (United States)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^t UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^u NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Everolimus; Immune checkpoint inhibitor; Nivolumab; Phase 3; Renal cell carcinoma

Indexed keywords

EVEROLIMUS; INTERLEUKIN 2; NIVOLUMAB; PAZOPANIB; SUNITINIB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CLINICAL OUTCOME; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTESTINE ISCHEMIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL CELL CARCINOMA; SEPTIC SHOCK; TREATMENT RESPONSE; AGE; CLINICAL TRIAL; COMPARATIVE STUDY; KAPLAN MEIER METHOD; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETREATMENT; RISK FACTOR; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, RENAL CELL; EVEROLIMUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETREATMENT; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85014412019     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.12.016     Document Type: Erratum

References (24)

1. Heng, D.Y., Xie, W., Regan, M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27 (2009), 5794–5799.
2. Motzer, R.J., Bacik, J., Schwartz, L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004), 454–463.
3. McKay, R.R., Kroeger, N., Xie, W., et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65 (2014), 577–584.
4. Calvo, E., Escudier, B., Motzer, R.J., et al. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48 (2012), 333–339.
5. Escudier, B., Michaelson, M.D., Motzer, R.J., et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 110 (2014), 2821–2828.
6. Taccoen, X., Valeri, A., Descotes, J.L., et al. Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol 51 (2007), 980–987.
7. Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
8. Opdivo (nivolumab) injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2015.
9. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
10. Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
11. Brookmeyer, R., Crowley, J., A confidence interval for the median survival time. Biometrics 38 (1982), 29–41.
12. Cox, D.R., Regression models and life tables. J R Stat Soc Series B Stat Methodol 34 (1972), 187–220.
13. Fagerland, M.W., Lydersen, S., Laake, P., Recommended confidence intervals for two independent binomial proportions. Stat Methods Med Res 24 (2015), 224–254.
14. Motzer, R.J., Escudier, B., Choueiri, T.K., Treatment of advanced renal-cell carcinoma. N Engl J Med 374 (2016), 888–890.
15. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
16. Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
17. Grimes, N.G., Devlin, J.M., Dunne, D.F., et al. A systematic review of the role of hepatectomy in the management of metastatic renal cell carcinoma. Eur J Surg Oncol 40 (2014), 1622–1628.
18. Vrdoljak, E., Rini, B., Schmidinger, M., et al. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 24 (2013), 431–440.
19. Stewart, G.D., O'Mahony, F.C., Laird, A., et al. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clin Cancer Res 21 (2015), 4212–4223.
20. Guislain, A., Gadiot, J., Kaiser, A., et al. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother 64 (2015), 1241–1250.
21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. Version 2.2016. www.nccn.org/professionals/physician_gls/f_guidelines.asp.
22. Kattan, M.W., Reuter, V., Motzer, R.J., Katz, J., Russo, P., A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001), 63–67.
23. Powles, T., Staehler, M., Ljungberg, B., et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 69 (2016), 4–6.
24. Escudier, B., Porta, C., Schmidinger, M., et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27 (2016), v58–v68.